|

Exemestane Clinical Trials

18 actively recruiting trials across 12 locations

Also known as: Aromasin, Aromasin®, FCE-24304

Pipeline

Phase 2: 7Phase 3: 9Phase 1/2: 2

Top Sponsors

  • AstraZeneca3
  • Merck Sharp & Dohme LLC2
  • Eli Lilly and Company2
  • Washington University School of Medicine1
  • University of Washington1

Indications

  • Cancer18
  • Breast Cancer17
  • Metastatic Breast Cancer3
  • Breast Cancer, Early Breast Cancer2
  • HER2-negative Breast Cancer2

Birmingham, Alabama3 trials

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Research Site

Phase 3
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Central Alabama Research

Phase 3
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

University of Alabama at Birmingham

Phase 2

Other2 trials

A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
Phase 2
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Phase 3

Anchorage, Alaska2 trials

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

Alaska Womens Cancer Care ( Site 0037)

Phase 2
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Alaska Oncology and Hematology

Phase 3

St Louis, Missouri2 trials

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Washington University School of Medicine

Phase 2
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Siteman Cancer Center at Washington University

Phase 2

Daphne, Alabama1 trial

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Southern Cancer Center, PC

Phase 3

Dothan, Alabama1 trial

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Research Site

Phase 3

Chandler, Arizona1 trial

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Ironwood Cancer & Research Centers

Phase 3

Gilbert, Arizona1 trial

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Research Site

Phase 3

Goodyear, Arizona1 trial

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

City of Hope - Phoenix ( Site 0006)

Phase 2

Tucson, Arizona1 trial

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Clinical Trial Site

Phase 3

Berkeley, California1 trial

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Berkeley Outpatient Center

Phase 2

Los Angeles, California1 trial

First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Ellison Clinic at Saint John's

Phase 1/2

New Haven, Connecticut1 trial

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Yale School of Medicine

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.